Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795997 | 0.87 | L3MBTL1 (0.32) | HCRTR1HCRTR2ADORA2AADORA3ADORA1 | |
| SCHEMBL796112 | 0.82 | KDM4E (0.33) | HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL795931 | 0.82 | TDP1 (0.36) | ADORA2AADORA3ADORA1L3MBTL1 | |
| SCHEMBL796521 | 0.77 | KDM4E (0.33) | HCRTR1HCRTR2ADORA2AL3MBTL1KDM6B | |
| SCHEMBL796437 | 0.77 | KDM4E (0.40) | ADORA2AADORA3ADORA1L3MBTL1 | |
| SCHEMBL808330 | 0.77 | CNR2 (0.39) | — | |
| SCHEMBL796498 | 0.77 | GRM5 (0.38) | L3MBTL1 | |
| SCHEMBL808336 | 0.76 | PTGIR (0.34) | HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL795809 | 0.76 | MAPT (0.36) | L3MBTL1 | |
| SCHEMBL795816 | 0.75 | ALDH1A1 (0.36) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | HCRTR1 537/4885HCRTR2 204/4885ADORA2A 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.